ReviewFrontiers in pharmacology2025
Yunnan Baiyao (YNBY): pharmacological mechanisms, therapeutic applications, and clinical evidence.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and Characterization of Ginsenoside-Aconitum Lipidic Cubic Nanoparticle-Loaded Dissolving Microneedles for Enhanced Transdermal Anti-inflammatory Therapy.AAPS PharmSciTech · 2026Article
- From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding.Frontiers in cardiovascular medicine · 2026Review
- Influences of applying Yunnan Baiyao aerosol combined with finger rehabilitation exercises on local complications of radial artery after transradial coronary intervention.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yunnan Baiyao (YNBY) is a traditional Chinese medicine widely used in hemostasis, anti-inflammation, antibacterial, analgesia and wound healing. This article reviews the research progress on the pharmacological mechanism, clinical application and safety of YNBY in the past two decades. Through systematic analysis of clinical trials, animal experiments and mechanistic studies, YNBY has shown significant effects in reducing surgical bleeding (such as reducing blood loss in orthognathic surgery by 21.4%), accelerating wound healing (such as increasing the healing rate of diabetic ulcers by 37%), regulating inflammation (such as inhibiting the expression of IL-6/CRP in arthritis), and inhibiting bacterial virulence (such as destroying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.